PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
2024-05-03
(Press-News.org) Study Title: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)

Publication: American Urological Association Annual Meeting Plenary, May 3, 2024

Dana-Farber Cancer Institute author: Xiao X. Wei, MD

Summary: In a follow-on analysis of results from the phase 3 PSMAfore study, clinical investigators from Dana-Farber and elsewhere found that clinical outcomes consistently favored 177Lu-PSMA-617 over a change from one androgen receptor pathway inhibitor (ARPI) to another, regardless of which ARPI patients received first. The trial enrolled 468 patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had progressed after one prior ARPI treatment and had never received taxane chemotherapy for metastatic disease. Patients who enrolled in the trial were assigned to either a change in ARPI, for example from abiraterone to enzalutamide or vice versa, or 177Lu-PSMA-617, a prostate-specific antigen (PSMA)-targeted radioligand therapy. This analysis found that treatment with 177Lu-PSMA-617 prolonged radiographic progression-free survival, improved PSA response rate, and increased objective response rate compared to a change in ARPI, regardless of whether patients had received prior abiraterone or enzalutamide. Those treated with 177Lu-PSMA-617 after abiraterone fared better than those previously treated with enzalutamide, though all results consistently favored 177Lu-PSMA-617 over a change to a different ARPI.

Significance: The approval of 177Lu-PSMA-617 for patients with mCRPC post-ARPI and post-taxane chemotherapy in March of 2022 based on the VISION clinical trial was a paradigm shift for the management of advanced prostate cancer. The PSMAfore clinical trial was designed to determine if 177Lu-PSMA-617 could also benefit a broader group of patients with mCRPC who have progressed on ARPI but have not received taxane chemotherapy. This data, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC.

Funding: Novartis

Contact:  Victoria Warren, 617-939-5531, victoria_warren@dfci.harvard.edu

END

[Attachments] See images for this press release:
Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition 2

ELSE PRESS RELEASES FROM THIS DATE:

Studies highlight need for tailored treatment options for women with peripheral artery disease

Studies highlight need for tailored treatment options for women with peripheral artery disease
2024-05-03
Late-Breaking Data Shows Endovascular Therapy Results in One-Third Reduction in Post-Procedural Complications for Women with PAD   Women and Asian Americans Less Likely to Undergo Endovascular Revascularization for PAD Compared to Men and Other Races    Long Beach, Calif. – May 3, 2024 – New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and revascularization. The data ...

Women and Black patients less likely to receive catheter-based treatment for pulmonary embolism

Women and Black patients less likely to receive catheter-based treatment for pulmonary embolism
2024-05-03
Long Beach, Calif. – May 3, 2024 – New data from the REAL-PE analysis investigated catheter-based pulmonary embolism (PE) treatment, showing women and Black people were less frequently treated with minimally invasive therapy compared to men or non-Black patients. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.                                                                                                              ...

Pilot program improves well-being of families during advanced care planning

2024-05-03
WASHINGTON (May 3, 2024) – Children with life-limiting rare diseases and their caregivers face tremendous stress and anxiety about the heart-breaking decisions before them. A new intervention – designed at Children’s National Hospital to support the palliative needs of these families – improved their spiritual and emotional well-being, according to new research published in the journal, Pediatrics.    Called FACE Rare (FAmily CEntered Pediatric Advance Care Planning Intervention for Rare Diseases), the counseling tools were found to be safe, effective and increased feelings of peace among families in this underserved ...

The key role of Galectin-3 in brain tumour development

2024-05-03
A research group at the Department of Biochemistry and Molecular Biology of the University of Seville has made a significant advance by discovering the crucial role of the protein Galectin-3 in the progression of various types of brain tumours. In these tumours, the most abundant immune system cells, microglia and macrophages, overexpress Galectin-3, which creates an immunosuppressed environment which inhibits the action of other immune cells against cancer cells. In vitro findings have shown that specific inhibition of Galectin-3 in microglial cells promotes expression of proinflammatory markers and reverses the presence of key immunosuppressive ...

Announcing Junevity as Tier 3 Sponsor of ARDD 2024

Announcing Junevity as Tier 3 Sponsor of ARDD 2024
2024-05-03
The University of Copenhagen is excited to announce Junevity as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online. Junevity is rewinding diseases of aging with novel transcription factor medicines. Based on 6 years of breakthrough research at UCSF, Junevity's REWINDTM platform identifies new targets based on large-scale genomics, machine learning, and cell aging experiments. Junevity is advancing multiple therapeutic programs towards ...

Climate change amplifies severity of combined wind-rain extremes over the UK and Ireland

2024-05-03
Climate change will cause an increase in extreme winter storms combining strong winds and heavy rainfall over the UK and Ireland, new research has shown. The new study was led by experts at Newcastle University and the Met Office and investigated how future climate change may influence compound wind-rain extremes, which are events where extreme wind and rainfall occur simultaneously. The researchers analysed data from climate simulations covering control (1981-2000) and future (2060-2081) periods, ...

Exeter announces new £3.4 million global funding for solutions to antifungal drug resistance

Exeter announces new £3.4 million global funding for solutions to antifungal drug resistance
2024-05-03
Researchers working on solutions for antifungal resistance are being encouraged to apply to a new £3.4 million fund led by the University of Exeter with UK government funding. The new fund, called FAILSAFE (Fungal AMR Innovations for LMICS: Solutions and Access For Everyone), is being launched by the University of Exeter’s MRC Centre for Medical Mycology, in partnership with the UK Department of Health and Social Care’s Global AMR Innovation Fund (GAMRIF). Life-threatening fungal diseases take as many lives annually as TB or malaria, but the organisms ...

In medieval England, leprosy spread between red squirrels and people, genome evidence shows

2024-05-03
Evidence from archaeological sites in the medieval English city of Winchester shows that English red squirrels once served as an important host for Mycobacterium leprae strains that caused leprosy in people, researchers report May 3 in the journal Current Biology. “With our genetic analysis we were able to identify red squirrels as the first ancient animal host of leprosy,” says senior author Verena Schuenemann of the University of Basel in Switzerland. “The medieval red squirrel strain we recovered is more closely related to medieval human strains from the same city than to strains isolated from infected ...

Source of pregnancy complications from infections revealed by placenta map

2024-05-03
The first panoramic view of infection pathways in the human placenta has been created, which could highlight potential drug targets to develop pregnancy-safe therapies for malaria, toxoplasmosis and listeria, all diseases that can cause severe pregnancy complications.     Researchers from the Wellcome Sanger Institute, the University of Cambridge, the University of Dundee, and collaborators, used novel ‘mini placenta’ models to map the placental response to infections in early development. This ...

Lepra in the middle ages: New insights on transmission pathways through squirrels

Lepra in the middle ages: New insights on transmission pathways through squirrels
2024-05-03
Researchers at the University of Basel and the University of Zurich have been able to prove that British squirrels carried leprosy bacteria as early as the Middle Ages. Further results revealed a link between the pathogens found in the medieval rodents and those in the local human population during that period. Skin spots, deformed noses, ulcers: leprosy, is an infectious disease that can bring about some serious symptoms. The bacterium responsible, Mycobacterium leprae, which still infects around 200,000 people each year especially in the Global South, also has a long history in Europe. The international research group led by paleogeneticist Professor Verena Schünemann ...

LAST 30 PRESS RELEASES:

Protective genetic mutation offers new hope for understanding autism and brain development

Colombia's Dr. Natalia Acosta-Baena uncovers critical link between brain development and degeneration

How can we reduce adolescent pregnancies in low- and middle-income countries?

When sun protection begets malnutrition: vitamin D deficiency in Japanese women

Cannabis use can cause chromosomal damage, increasing cancer risk and harming offspring

Survey finds many Americans apply misguided and counterproductive advice to combat holiday weight gain

New study reveals half a century of change on Britain’s iconic limestone pavements

Green flight paths could unlock sustainable aviation, new research suggests

Community partners key to success of vaccine clinic focused on neurodevelopmental conditions

Low-carbon collaborative dual-layer optimization for energy station considering joint electricity and heat demand response

McMaster University researchers uncover potential treatment for rare genetic disorders

The return of protectionism: The impact of the Sino-US trade war

UTokyo and NARO develop new vertical seed distribution trait for soybean breeding

Research into UK’s use of plastic packaging finds households ‘wishcycle’ rather than recycle – risking vast contamination

Vaccine shows promise against aggressive breast cancer

Adverse events affect over 1 in 3 surgery patients, US study finds

Outsourcing adult social care has contributed to England’s care crisis, argue experts

The Lancet: Over 800 million adults living with diabetes, more than half not receiving treatment, global study suggests

New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality

Plugged wells and reduced injection lower induced earthquake rates in Oklahoma

Yin selected as a 2024 American Society of Agronomy Fellow

Long Covid could cost the economy billions every year

Bluetooth technology unlocks urban animal secrets

This nifty AI tool helps neurosurgeons find sneaky cancer cells

Treatment advances, predictive biomarkers stand to improve bladder cancer care

NYC's ride-hailing fee failed to ease Manhattan traffic, new NYU Tandon study reveals

Meteorite contains evidence of liquid water on Mars 742 million years ago

Self-reported screening helped reduce distressing symptoms for pediatric patients with cancer

Which risk factors are linked to having a severe stroke?

Opening borders for workers: Abe’s profound influence on Japan’s immigration regime

[Press-News.org] Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition